-
T-Cell Involver
Program Target Indication Mono/Combo preclinical IND-Enabling Phase 1 phase 2 Rights DNV3 LAG-3 Solid Tumors Mono Global Malignant Melanoma +Toripalimab*+ Chemo* -
Mechanism of Action: Anti-LAG-3 monoclonal antibodyIndication: Solid tumorsDevelopment Plan: Clinical trial ongoing in ChinaPreclinical Highlights: Strong immune activation in xenogeneic modelsPartnering Status: Open to co-development / licensing
-
-
T-Cell Engager (TCE)
Program Platform Target Indication Mono/Combo Preclinical IND-Enabling Phase 1 phase 2 Rights SMET12 H-BiTE? EGFR × CD3 Solid Tumors Mono Global Solid Tumors +Toripalimab* CMD011 H-BiTE? GPC3 × CD3 Hepatocellular Carcinoma Mono Global CMDE005 Pro-BiTE? EGFR × CD3 Solid Tumors Mono Global Undisclosed Pro-BiTE? Undisclosed Solid Tumors Mono Global -
Mechanism of Action: H-BiTE? with EGFR × CD3Indication: Solid tumorsDevelopment Plan: Clinical trial ongoing in China; US IND cleared by FDAPreclinical Highlights: Excellent manufacturability and stabilityPartnering Status: Open to co-development / licensing
-
CMD011 - Project DetailMechanism of Action: Hepatocellular Carcinoma (HCC)Indication: Solid tumorsDevelopment Plan: Clinical trial ongoing in China; US IND cleared by FDAPreclinical Highlights: Strong and selective binding to GPC3+ tumor cells with minimal off-target reactivityPartnering Status: Open to co-development / licensing
-
CMDE005 - Project DetailMechanism of Action: Pro-BiTE? with EGFR × CD3Indication: Solid tumorsDevelopment Plan: Clinical trial ongoing in China; US IND cleared by FDAPreclinical Highlights: Inactive in normal tissue environments, selectively activated in TME by tumor-expressed enzymesPartnering Status: Open to co-development / licensing
-
Undisclosed
-
-
Multifunctional T-Cell Engager (mTCE)
Program Platform Target Indication Mono/Combo preclinical IND-Enabling Phase 1 phase 2 Rights Undisclosed Tri-Specific Antibody Undisclosed Undisclosed Mono Global -
Undisclosed
-
*
Toripalimab and Chemo are Externally Soruced and Not Proprietary
Single-Nation Development in China
Global Development
- Mono = Monotherapy
- Combo = Combination Therapy
- IND = Investigational New Drug